| abstract |
The present invention provides a target proteolytic enzyme-sensitive anticancer agent precursor that minimizes the destruction of normal cells and provides a high anticancer therapeutic effect by administration of a low anticancer agent and irradiation dose. The present invention relates to an anticancer agent, a peptide that is specifically decomposed by a target proteolytic enzyme that is excessively secreted from cancer cells, and a target proteolytic enzyme that is bound by a polymer that can specifically accumulate at the cancer site. When an inactive form of an anticancer agent precursor is administered, it accumulates at the target site and then releases the active anticancer agent from the target site while the peptide is decomposed by irradiation. Therefore, the destruction of normal cells can be minimized, and a high anticancer treatment effect can be obtained by administration of a low anticancer agent and irradiation dose. [Selection] Figure 1 |